Novartis

Novartis Alcon changes build better platform for ophthalmologyAlcon Laboratories pharmaceutical products have been moved into the Novartis Pharmaceutical Division. The switch means a sharper focus on research and development in ophthalmology as well as better access to Norvartis’ patient services and support capabilities.
Combination pack approved for breast cancer treatmentFDA approves ribociclib plus letrozole to treat a subset of advanced breast cancer patients.
Aflibercept rivals laser for diabetic retinopathyIntravitreal aflibercept worked better than panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR) in a new head-to-head trial, according to researchers.
FDA approves first targeted leukemia drug for certain patients, plus 2 moreLate last week, FDA approved a new drug to treat acute myeloid leukemia (AML), the first treatment for Batten disease, and expanded the use of a current drug to treat liver cancer.
Preparing your patient for PRKPhotorefractive keratectomy (PRK) was the original excimer laser procedure approved by the FDA—and is still a safe and effective treatment of refractive errors. PRK has the benefits of no-flap creation; therefore, there is no risk of flap complications.
How to combat vernal keratoconjunctivitisIt is a precarious position considering the desire to find the perfect remedy— yet with vernal keratoconjunctivitis (VKC), there is no magic bullet.
Novel drug reduces monthly migraine daysA global phase 3 study of erenumab (Amgen and Novartis) showed that the drug was able to prevent migraines headaches.
Clear skin within reach for psoriasis patientsNew data presented at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, this week shows that secukinumab (Cosentyx, Novartis) has long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis.
Novartis announces new Cosentyx data in psoriasis treatment, including long-term studyResearchers presented new data on the use of the fully human IL-17A inhibitor Cosentyx (secukinumab, Novartis) in moderate-to-severe psoriasis, at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, September 28 through October 2, 2016.
First "artificial pancreas" for diabetes approved, plus 2 more FDA actionsFDA recently approved several medications and devices across several therapy areas: diabetes, weight loss and rare, auto-inflammatory diseases. Here are the top 3 new approvals.